Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cytogenetics in multiple myeloma patients progressing into extramedullary disease

L. Besse, L. Sedlarikova, H. Greslikova, R. Kupska, M. Almasi, M. Penka, T. Jelinek, L. Pour, Z. Adam, P. Kuglik, M. Krejci, R. Hajek, S. Sevcikova,

. 2016 ; 97 (1) : 93-100. [pub] 20151019

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17014248

Grantová podpora
NT14575 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myeloma patients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization. MATERIAL AND METHODS: Thirty-one patients [25 BM plasma cells (BMPCs), 18 extramedullary tumor plasma cells], of which 12 had paired samples of BM and extramedullary plasma cells and 14 had previous collection of BM, were investigated for the presence of chromosomal aberrations (CHAs): del(17)(p13), del(13)(q14), 14q32 disruption, t(4;14)(p16;q32), t(14;16)(q32;q23), gain(1)(q21), and hyperdiploidy status. RESULTS: Overall, in unrelated samples, t(4;14) was more prevalent in extramedullary plasma cells, and hyperdiploidy was more frequent in BMPCs. In paired samples, there was a higher frequency of del(13)(q14) and 14q32 disruption in BMPCs. Frequency of all studied CHAs was higher in BMPCs of extramedullary patients than in their previous sample collection. CONCLUSION: These data show that plasma cells harbor more aberrations during their transformation into extramedullary form.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014248
003      
CZ-PrNML
005      
20200219094236.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12688 $2 doi
035    __
$a (PubMed)26432667
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bešše, Lenka, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $d 1985- $7 mub2014851432
245    10
$a Cytogenetics in multiple myeloma patients progressing into extramedullary disease / $c L. Besse, L. Sedlarikova, H. Greslikova, R. Kupska, M. Almasi, M. Penka, T. Jelinek, L. Pour, Z. Adam, P. Kuglik, M. Krejci, R. Hajek, S. Sevcikova,
520    9_
$a BACKGROUND: Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myeloma patients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization. MATERIAL AND METHODS: Thirty-one patients [25 BM plasma cells (BMPCs), 18 extramedullary tumor plasma cells], of which 12 had paired samples of BM and extramedullary plasma cells and 14 had previous collection of BM, were investigated for the presence of chromosomal aberrations (CHAs): del(17)(p13), del(13)(q14), 14q32 disruption, t(4;14)(p16;q32), t(14;16)(q32;q23), gain(1)(q21), and hyperdiploidy status. RESULTS: Overall, in unrelated samples, t(4;14) was more prevalent in extramedullary plasma cells, and hyperdiploidy was more frequent in BMPCs. In paired samples, there was a higher frequency of del(13)(q14) and 14q32 disruption in BMPCs. Frequency of all studied CHAs was higher in BMPCs of extramedullary patients than in their previous sample collection. CONCLUSION: These data show that plasma cells harbor more aberrations during their transformation into extramedullary form.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a kostní dřeň $x patologie $7 D001853
650    12
$a chromozomální aberace $7 D002869
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x diagnóza $x genetika $x patologie $7 D009101
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a translokace genetická $7 D014178
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sedlaříková, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 xx0214571
700    1_
$a Grešliková, Henrieta $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0122004
700    1_
$a Kupská, Renata $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0128684
700    1_
$a Almasi, Martina $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 gn_A_00004597
700    1_
$a Penka, Miroslav, $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $d 1952- $7 nlk19990073680
700    1_
$a Jelínek, Tomáš, $u Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic. $d 1986- $7 xx0230997
700    1_
$a Pour, Luděk $u Department of Internal Medicine - Hematooncology, University Hospital Brno, Brno, Czech Republic. $7 xx0102556
700    1_
$a Adam, Zdeněk $u Department of Internal Medicine - Hematooncology, University Hospital Brno, Brno, Czech Republic. $7 jn19981000018
700    1_
$a Kuglík, Petr, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $d 1957- $7 ola2003204793
700    1_
$a Krejčí, Marta, $u Department of Internal Medicine - Hematooncology, University Hospital Brno, Brno, Czech Republic. $d 1969- $7 jx20080512017
700    1_
$a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic. $d 1964- $7 nlk20000083645
700    1_
$a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 mub2015859787
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 97, č. 1 (2016), s. 93-100
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26432667 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20200219094639 $b ABA008
999    __
$a ok $b bmc $g 1200713 $s 975026
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 97 $c 1 $d 93-100 $e 20151019 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a NT14575 $p MZ0
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace